Russian Journal of OncologyRussian Journal of OncologyРоссийский онкологический журнал1028-99842412-9119Eco-Vector4013210.17816/onco40132ArticlesСтатьиResearch ArticleMolecular genetic features of peritoneal mesotheliomaМолекулярно-генетические особенности мезотелиомы брюшиныAbdullaevAmir G.АбдуллаевАмир Гусейнович

МD

научн. сотр. отд-ния хирургического торакального НИИ клинической онкологии

agulsky@rambler.ruShakhpazyanN. KШахпазянН. КPolockiyB. EПолоцкийБ. ЕMekhedaL. VМехедаЛ. ВDavydovM. IДавыдовМ. ИN.N. Blokhin Russian Cancer Research Center under the Russian Academy of Medical SciencesФГБУ «Российский онкологический научный центр им. Н.Н. Блохина» РАМН15102014195VOL 19, NO5 (2014)ТОМ 19, №5 (2014)525622072020Copyright ©; 2014, Eco-VectorCopyright ©; 2014, ООО "Эко-Вектор"2014Eco-VectorООО "Эко-Вектор"https://rjonco.com/1028-9984/article/view/40132

The article analyzes the molecular genetic features ofperitoneal mesothelioma in order to identify differential diagnostic signs of the disease, to identify the factors of tumor growth, as well as identifying ways to improve current treatments.

В статье проведен анализ молекулярно-генетических особенностей мезотелиомы брюшины с целью выявления дифференциально-диагностических признаков этого заболевания, определения основных факторов опухолевого роста, а также выявления путей улучшения современных методов лечения.

peritoneal mesotheliomapleural mesotheliomahyperthermic intraperitoneal chemoperfusionimmunohistochemical studyмезотелиома брюшинымезотелиома плеврыгипертермическая интраперитонеальная химиоперфузияиммуногистохимическое исследованиеhttp://cancer.sanger.ac.uk/cosmic/browse/tissue#sn=pleura&ss=all&hn=mesothelioma&sh=all&in=t&src=tissuehttp://cancer.sanger.ac.uk/cosmic/browse/tissue#sn=peritoneum&ss=all&hn=mesothelioma&sh=all&in=t&src=tissueJanne P.A., Wozniak A.J., Belani C.P., Keohan M.L., Ross H.J. Polikoff J.A. et al. Open-label study of pemetrexed alone or in combination with cisplatin for the treatment of patients with peritoneal mesothelioma: outcomes of an expanded access program. Clin. Lung. Cancer. 2005; 7(1): 40-6.Foster J.M., Radhakrishna U., Govindarajan V., Carreau J.H., Gatalica Z., Sharma P. et al. Clinical implications of novel activating EGFR mutations in malignant peritoneal mesothelioma. World J. Surg. Oncol. 2010; 8: 88.Enomoto Y., Kasai T., Takeda M., Takano M., Morita K., Kadota E. et al. A comparison of epidermal growth factor receptor expression in malignant peritoneal and pleural mesothelioma. Pathol. Int. 2012; 62(4): 226-31.Kalra N., Ashai A., Xi L., Zhang J., Avital I., Raffeld M., Hassan R. Patients with peritoneal mesothelioma lack epidermal growth factor receptor tyrosine kinase mutations that would make them sensitive to tyrosine kinase inhibitors. Oncol. Rep. 2012; 27(6): 1794-800.Ribeiro C., Campelos S., Moura C.S., Machado J.C., Justino A., Parente B. Well-differentiated papillary mesothelioma: clustering in a Portuguese family with a germline BAP1 mutation. Ann. Oncol. 2013; 24(8): 2147-50.Testa J.R., Cheung M., Pei J., Below J.E., Tan Y., Sementino E. et al. Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet. 2011; 43(10): 1022-5.Langlais S., Velazquez-Martin J.P., Dube P., Simpson E.R. et al. Ocular melanoma in a patient successfully treated for diffuse malignant peritoneal mesothelioma: a case report. World. J. Surg. Oncol. 2012; 10: 90.Pilarski R., Cebulla C.M., Massengill J.B., Rai K., Rich T., Strong L. et al. Expanding the clinical phenotype of hereditary BAP1 cancer predisposition syndrome, reporting three new cases. Genes Chromosom. Cancer. 2014; 53(2): 177-82.Ceelen W.P., Van Dalen T., Van Bockstal M., Libbrecht L., Sijmons R.H. Malignant peritoneal mesothelioma in a patient with Li-Fraumeni syndrome. J. Clin. Oncol. 2011; 29(17): e503-5.Husain A.N., Colby T.V., Ordonez N.G., Krausz T., Borczuk A., Cagle P.T. et al. Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group. Arch. Pathol. Lab. Med. 2009; 133(8): 1317-31.Marchevsky A.M. Application of immunohistochemistry to the diagnosis of malignant mesothelioma. Arch. Pathol. Lab. Med. 2008; 132(3): 397-401.Husain A.N. Colby T., Ordonez N., Krausz T., Attanoos R., Beasley M.B. et al. Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group. Arch. Pathol. Lab. Med. 2013; 137(5): 647-67.Kindler H.L. Peritoneal mesothelioma: the site of origin matters. American Society of Clinical Oncology Educational Book. 2013: 182-8.Yaziji H., Battifora H., Barry T.S., Hwang H.C., Bacchi C.E., McIntosh M.W. et al. Evaluation of 12 antibodies for distinguishing epithelioid mesothelioma from adenocarcinoma: identification of a three-antibody immunohistochemical panel with maximal sensitivity and specificity. Mod. Pathol. 2006; 19(4): 514-23.Gao F.F., Krasinskas A.M., Chivukula M. Is PAX2 a reliable marker in differentiating diffuse malignant mesotheliomas of peritoneum from serous carcinomas of mullerian origin? Appl. Immunohistochem Mol. Morphol. 2012; 20(3): 272-6.Taskm S., Gumus Y, Kiremitci S., Kahraman K., Sertcelik A., Ortac F. Malignant peritoneal mesothelioma presented as peritoneal adenocarcinoma or primary ovarian cancer: case series and review of the clinical and immunohistochemical features. Int. J. Clin. Exp. Pathol. 2012; 5(5): 472-8.Ordonez N.G. Value of claudin-4 immunostaining in the diagnosis of mesothelioma. Am. J. Clin. Pathol. 2013 May; 139(5): 611-9.Sandeck H.P., Roe O.D., Kjaerheim K., Willen H., Larsson E. Reevaluation of histological diagnoses of malignant mesothelioma by immunohistochemistry. Diagn Pathol. 2010; 5: 47.Attanoos R.L., Griffin A. Gibbs A.R. The use of immunohistochemistry in distinguishing reactive from neoplastic mesothelium: a novel use for desmin and comparative evaluation with epithelial membrane antigen, p53, platelet-derived growth factor-receptor, P-glycoprotein and Bcl-2. Histopathology. 2003. 43: 231-8.Shih C.A., Ho S.P., Tsay F.W., Lai K.H., Hsu P.I. Diffuse malignant peritoneal mesothelioma. Kaohsiung J. Med. Sci. 2013; 29(11): 642-5.Vyas D., Pihl K., Kavuturu S., Vyas A. Mesothelioma as a rapidly developing Giant Abdominal Cyst. World J. Surg. Oncol. 2012; 10: 277.Comin C.E., Saieva C., Messerini L. h-caldesmon, calretinin, estrogen receptor, and Ber-EP4: a useful combination of immunohistochemical markers for differentiating epithelioid peritoneal mesothelioma from serous papillary carcinoma of the ovary. Am J. Surg Pathol. 2007; 31(8): 1139-48.Ordonez N.G. Value of PAX8, PAX2, claudin-4, and h-caldesmon immunostaining in distinguishing peritoneal epithelioid mesotheliomas from serous carcinomas. Mod Pathol. 2013; 26(4): 553-62.Ordonez N.G. Value of PAX8, PAX2, napsin A, carbonic anhydrase IX, and claudin-4 immunostaining in distinguishing pleural epithelioid mesothelioma from metastatic renal cell carcinoma. ModPathol. 2013; 26(8): 1132-43.Ordonez N.G. Application of immunohistochemistry in the diagnosis of epithelioid mesothelioma: a review and update. Hum. Pathol. 2013; 44(1): 1-19.Hwang H., Tse C., Rodriguez S., Gown A., Churg A. p16 FISH Deletion in Surface Epithelial Mesothelial Proliferations Is Predictive of Underlying Invasive Mesothelioma. Am. J. Surg. Pathol. 2014 May; 38(5): 681-8.Malpica A., Sant’Ambrogio S., Deavers M.T. Silva E.G. Well-differentiated papillary mesothelioma of the female peritoneum: a clinicopathologic study of 26 cases. Am. J. Surg. Pathol. 2012; 36(1): 117-27.Baratti D., Vaira M., Kusamura S., D’Amico S., Balestra M.R., Cioppa T. et al. Multicystic peritoneal mesothelioma: outcomes and patho-biological features in a multi-institutional series treated by cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC). Eur. J. Surg. Oncol. 2010; 36(11): 1047-53.Pillai K., Pourgholami M.H., Chua T.C., Morris D.L. Ki67-BCL2 index in prognosis of malignant peritoneal mesothelioma. Am. J. Cancer Res. 2013; 3(4): 411-23.Pillai K., Pourgholami M.H. Chua T.C., Morris D.L. Does the expression of BCL2 have prognostic significance in malignant peritoneal mesothelioma? Am. J. Cancer Res. 2013; 3(3): 312-22.Goparaju C., Donington J.S., Hsu T., Harrington R., Hirsch N., Pass H.I. Overexpression of EPH receptor B2 in malignant mesothelioma correlates with oncogenic behavior. J. Thorac. Oncol. 2013; 8(9): 1203-11.Sekido Y. Molecular pathogenesis of malignant mesothelioma. Carcinogenesis. 2013; 34(7): 1413-9.Krasinskas A.M., Bartlett D.L., Cieply K., Dacic S. CDKN2A and MTAP deletions in peritoneal mesotheliomas are correlated with loss of p16 protein expression and poor survival. Mod. Pathol. 2010; 23(4): 531-8.Destro A., Ceresoli G.L., Baryshnikova E., Garassino I., Zucali P.A., De Vincenzo F. et al. Gene methylation in pleural mesothelioma: correlations with clinico-pathological features and patient’s follow-up. Lung Cancer. 2008; 59(3): 369-76.Hama R., Watanabe Y., Shinada K., Yamada Y., Ogata Y., Yoshida Y. et al. Characterization of DNA hypermethylation in two cases of peritoneal mesothelioma. Tumour Biol. 2012; 33(6): 2031-40.Kusamura S., Baratti D., Zaffaroni N., Villa R., Laterza B., Balestra M.R., Deraco M. Pathophysiology and biology of peritoneal carcinomatosis. World J. Gastrointest. Oncol. 2010; 2(1): 12-8.Villa R., Daidone M.G., Motta R., Venturini L., De Marco C., Vannelli A. et al. N. Multiple mechanisms of telomere maintenance exist and differentially affect clinical outcome in diffuse malignant peritoneal mesothelioma. Clin. Cancer Res. 2008; 14(13): 4134-40.Ueno T., Toyooka S., Fukazawa T., Kubo T., Soh J., Asano H. et al. Preclinical evaluation of microRNA-34b/c delivery for malignant pleural mesothelioma. Acta Med. Okayama. 2014; 68(1): 23-6.Zaffaroni N., Costa A., Pennati M., De Marco C., Affini E., Madeo M. et al. Survivin is highly expressed and promotes cell survival in malignant peritoneal mesothelioma. Cell Oncol. 2007; 29: 453-66.Pillai K., Pourgholami M.H., Chua T.C., Morris D.L. Oestrogen receptors are prognostic factors in malignant peritoneal mesothelioma. J. Cancer Res. Clin. Oncol. 2013; 139(6): 987-94.Pillai K., Pourgholami M.H., Chua T.C., Morris D.L. MUC1 has prognostic significance in malignant peritoneal mesothelioma. Int. J. Biol. Markers. 2013; 28(3): 303-12.Lopez-Lago M.A., Okada T., Murillo M.M., Socci N., Giancotti F.G. Loss of the tumor suppressor gene NF2, encoding merlin, constitutively activates integrin-dependent mTORC1 signaling. Mol. Cell. Biol. 2009; 29(15): 4235-49.Turner K., Varghese S., Alexander H.R.Jr. Current concepts in the evaluation and treatment of patients with diffuse malignant peritoneal mesothelioma. J. Natl Compr. Canc. Netw. 2012; 10(1): 49-57.Cioce M., Canino C., Goparaju C., Yang H., Carbone M., Pass H.I. Autocrine CSF-1R signaling drives mesothelioma chemoresistance via AKT activation. Cell Death Dis. 2014; 5:e1167. doi: 10.1038/cddis.2014.136.Sekido Y. Genomic abnormalities and signal transduction dysregulation in malignant mesothelioma cells. Cancer Sci. 2010; 101(1): 1-6.Izzi V., Masuelli L., Tresoldi I., Foti C., Modesti A., Bei R. Immunity and malignant mesothelioma: from mesothelial cell damage to tumor development and immune response-based therapies. Cancer Lett. 2012; 322(1): 18-34.Shukla A., Miller J.M., Cason C., Sayan M., MacPherson M.B., Beuschel S.L. et al. Extracellular signal-regulated kinase 5: a potential therapeutic target for malignant mesotheliomas. Clin. Cancer Res. 2013; 19(8): 2071-83.Tang Z., Qian M., Ho M. The role of mesothelin in tumor progression and targeted therapy. Anticancer Agents Med. Chem. 2013; 13(2): 276-80.Sekido Y. Inactivation of Merlin in malignant mesothelioma cells and the Hippo signaling cascade dysregulation. Pathol Int. 2011; 61(6): 331-44.Capkova L., Koubkova L., Kodet R. Expression of carbonic anhydrase IX (CAIX) in malignant mesothelioma. An immunohistochemical and immunocytochemical study. Neoplasma. 2014; 61(2): 161-9.Zimling Z.G., Sorensen J.B., Gerds T.A., Bech C., Andersen C. B., Santoni-Rugiu E. A biomarker profile for predicting efficacy of cisplatin-vinorelbine therapy in malignant pleural mesothelioma. Cancer Chemother. Pharmacol. 2012; 70(5): 743-54.Ting S., Mairinger F.D., Hager T., Welter S., Eberhardt W.E., Wohlschlaeger J. et al. ERCC1, MLH1, MSH2, MSH6, and PIII-tubulin: resistance proteins associated with response and outcome to platinum-based chemotherapy in malignant pleural mesothelioma. Clin. Lung Cancer. 2013; 14(5): 558-67.Takeuchi S., Seike M., Noro R., Soeno C., Sugano T., Zou F. et al. Significance of osteopontin in the sensitivity of malignant pleural mesothelioma to pemetrexed. Int J. Oncol. 2014; 44(6): 1886-94.